Get the Stockscreener App
83.49
1.14%
-0.96
After Hours:
83.49
Haemonetics Corp stock is traded at $83.49, with a volume of 949.29K.
It is down -1.14% in the last 24 hours and up +14.18% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$84.45
Open:
$83.84
24h Volume:
949.29K
Relative Volume:
0.98
Market Cap:
$3.91B
Revenue:
$1.35B
Net Income/Loss:
$163.34M
P/E Ratio:
25.48
EPS:
3.2763
Net Cash Flow:
$189.17M
1W Performance:
-0.54%
1M Performance:
+14.18%
6M Performance:
+17.00%
1Y Performance:
+1.45%
1-Day Range:
$82.07
$84.50
1-Week Range:
$82.07
$87.32
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
83.49 | 3.95B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics (HAE) Receives Updated Neutral Rating with Raised Pr - GuruFocus
Haemonetics price target raised to $74 from $62 at JPMorgan - TipRanks
Is it Apt to Retain Haemonetics Stock in Your Portfolio Now? - Yahoo Finance
Why Haemonetics (HAE) Stock Is Down Today - Finviz
Haemonetics (HAE) Downgraded to Neutral by Citigroup, Raises Pri - GuruFocus
Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77 - marketscreener.com
Haemonetics downgraded to Neutral from Buy at Citi - TipRanks
BofA Securities Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $90 - 富途牛牛
Haemonetics price target raised to $90 from $75 at BofA - TipRanks
Marshall Wace LLP Lowers Holdings in Haemonetics Corporation $HAE - MarketBeat
Norges Bank Makes New $36.82 Million Investment in Haemonetics Corporation $HAE - MarketBeat
Haemonetics (HAE): Reassessing Valuation After a 55% Three-Month Share Price Surge - simplywall.st
Haemonetics (NYSE:HAE) Reaches New 52-Week HighHere's Why - MarketBeat
Haemonetics Corporation $HAE Shares Acquired by Walleye Capital LLC - MarketBeat
XTX Topco Ltd Sells 24,831 Shares of Haemonetics Corporation $HAE - MarketBeat
Should You Be Adding Haemonetics (NYSE:HAE) To Your Watchlist Today? - Yahoo Finance
Capital Fund Management S.A. Makes New $995,000 Investment in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (NYSE:HAE) Enhances Medical Innovation - Kalkine Media
Wall Street Zen Upgrades Haemonetics (NYSE:HAE) to "Buy" - MarketBeat
Haemonetics Corporation (NYSE:HAE) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Haemonetics stock hits 52-week high at $85.07 By Investing.com - Investing.com Canada
Haemonetics leverages insights from MassWomen conference - Traders Union
QSV Equity Investors LLC Makes New Investment in Haemonetics Corporation $HAE - MarketBeat
Can Haemonetics Corporation (HAZ) stock sustain free cash flowWeekly Profit Report & Long-Term Capital Growth Ideas - Newser
Will Haemonetics Corporation (HAZ) stock extend growth storyWeekly Trade Report & Technical Confirmation Trade Alerts - Newser
Will Haemonetics Corporation (HAZ) stock issue positive guidanceInsider Selling & Real-Time Stock Movement Alerts - Newser
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
3-in-1 TAVR guidewire linked to faster procedures, less radiation - Cardiovascular Business
Fisher Asset Management LLC Cuts Position in Haemonetics Corporation $HAE - MarketBeat
Why Haemonetics Corporation stock could outperform next year2025 Market Outlook & High Conviction Buy Zone Alerts - Newser
Blood Bank Information Systems Market Projections 2025-2032: - openPR.com
Top 2 Health Care Stocks You May Want To Dump This Month - Sahm
Haemonetics Corporation $HAE Stock Position Increased by River Road Asset Management LLC - MarketBeat
TradeLink Capital LLC Acquires 5,128 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Schroder Investment Management Group - MarketBeat
Rhumbline Advisers Purchases 5,284 Shares of Haemonetics Corporation $HAE - MarketBeat
How Haemonetics Corporation stock benefits from digital adoptionEarnings Recap Report & Daily Oversold Stock Bounce Ideas - Newser
Can Haemonetics Corporation (HAZ) stock test all time highs2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
Will Haemonetics Corporation stock recover faster than peersStock Surge & Scalable Portfolio Growth Ideas - Newser
Why retail traders accumulate Haemonetics Corporation stockQuarterly Earnings Summary & Verified Swing Trading Watchlist - Newser
Boston Partners Buys 11,738 Shares of Haemonetics Corporation $HAE - MarketBeat
Q1 EPS Estimates for Haemonetics Boosted by Zacks Research - MarketBeat
Is There Opportunity in Haemonetics After Shares Surge 57% on Expansion News? - simplywall.st
Q3 EPS Estimates for Haemonetics Decreased by Zacks Research - MarketBeat
Haemonetics Reaches Analyst Target Price - Nasdaq
Haemonetics Corporation $HAE Stock Position Raised by Geode Capital Management LLC - MarketBeat
BTIG Research Reiterates "Buy" Rating for Haemonetics (NYSE:HAE) - MarketBeat
Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know - Barchart.com
Haemonetics stock holds Buy rating at BTIG on plasma segment strength - Investing.com
HAE: BTIG Reiterates Buy Rating with $88 Price Target | HAE Stoc - GuruFocus
How currency fluctuations impact Haemonetics Corporation stockEarnings Risk Report & Daily Oversold Stock Bounce Ideas - newser.com
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):